文献速递肝病消化道肿瘤与早癌

纤维化严重程度决定晚期非酒精性脂肪性肝病患者病因特异性死亡率:一项多国队列研究

Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
PubMed 文献 · Gastroenterology · 2018-05-05

中位随访5.5年期间,肝硬化患者以肝脏相关事件为主,而F3纤维化患者以非肝脏恶性肿瘤和血管事件为主。

要点

  • F3纤维化患者10年无移植生存率94%,高于肝硬化Child-Turcotte-Pugh A5的74%和A6的17%。
  • 肝硬化患者肝失代偿和肝细胞癌累积发生率高于F3纤维化患者。
  • F3纤维化患者血管事件和非肝脏恶性肿瘤累积发生率高于肝硬化患者。

核心结论

  • NAFLD肝硬化患者以肝脏相关事件为主,而桥接纤维化患者以非肝脏恶性肿瘤和血管事件为主。

研究设计与样本

  • 患者于1995年4月至2013年11月期间在西班牙、澳大利亚、香港和古巴的肝病中心接受评估,随访至2016年12月、死亡或肝移植。
  • 采用Cox比例风险和竞争风险模型估计无移植生存率和主要临床事件发生率,并识别与结局相关的因素。

主要发现

  • 平均随访5.5年(范围2.7-8.2年)期间,37例死亡,37例接受肝移植,88例发生首次肝失代偿事件,41例发生肝细胞癌,14例发生血管事件,30例发生非肝脏恶性肿瘤。
  • F3纤维化患者10年无移植生存率为94%(95%CI 86%-99%),高于肝硬化Child-Turcotte-Pugh A5患者的74%(95%CI 61%-89%)和A6患者的17%(95%CI 6%-29%)。
  • 肝硬化患者肝失代偿累积发生率为44%(95%CI 32%-60%),高于F3纤维化患者的6%(95%CI 2%-13%);肝细胞癌累积发生率肝硬化患者为17%(95%CI 8%-31%),高于F3纤维化患者的2.3%(95%CI 1%-12%)。
  • F3纤维化患者血管事件累积发生率为7%(95%CI 3%-18%),高于肝硬化患者的2%(95%CI 0%-6%);非肝脏恶性肿瘤累积发生率F3纤维化患者为14%(95%CI 7%-23%),高于肝硬化患者的6%(95%CI 2%-15%)。
  • 死亡或移植、肝失代偿和肝细胞癌与基线肝硬化和轻度(<33%)脂肪变独立相关,而中度饮酒仅与肝硬化患者的这些结局相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Little is known about the natural course of nonalcoholic fatty liver disease (NAFLD) with advanced fibrosis. We describe long-term outcomes and evaluate the effects of clinical and histologic parameters on disease progression in patients with advanced NAFLD. METHODS: We conducted a multi-national study of 458 patients with biopsy-confirmed NAFLD with bridging fibrosis (F3, n = 159) or compensated cirrhosis (222 patients with Child-Turcotte-Pugh scores of A5 and 77 patients with scores of A6), evaluated from April 1995 through November 2013 and followed until December 2016, death, or liver transplantation at hepatology centers in Spain, Australia, Hong Kong, and Cuba. Biopsies were re-evaluated and scored; demographic, clinical, laboratory, and pathology data for each patient were collected from the time of liver biopsy collection. Cox proportional and competing risk models were used to estimate rates of transplantation-free survival and major clinical events and to identify factors associated with outcomes. RESULTS: During a mean follow-up time of 5.5 years (range, 2.7-8.2 years), 37 patients died, 37 received liver transplants, 88 had initial hepatic decompensation events, 41 developed hepatocellular carcinoma, 14 had vascular events, and 30 developed nonhepatic cancers. A higher proportion of patients with F3 fibrosis survived transplantation-free for 10 years (94%; 95% confidence interval [CI], 86%-99%) than of patients with cirrhosis and Child-Turcotte-Pugh A5 (74%; 95% CI, 61%-89%) or Child-Turcotte-Pugh A6 (17%; 95% CI, 6%-29%). Patients with cirrhosis were more likely than patients with F3 fibrosis to have hepatic decompensation (44%; 95% CI, 32%-60% vs 6%, 95% CI, 2%-13%) or hepatocellular carcinoma (17%; 95% CI, 8%-31% vs 2.3%, 95% CI, 1%-12%). The cumulative incidence of vascular events was higher in patients with F3 fibrosis (7%; 95% CI, 3%-18%) than cirrhosis (2%; 95% CI, 0%-6%). The cumulative incidence of nonhepatic malignancies was higher in patients with F3 fibrosis (14%; 95% CI, 7%-23%) than cirrhosis (6%; 95% CI, 2%-15%). Death or transplantation, decompensation, and hepatocellular carcinoma were independently associated with baseline cirrhosis and mild (<33%) steatosis, whereas moderate alcohol consumption was associated with these outcomes only in patients with cirrhosis. CONCLUSIONS: Patients with NAFLD cirrhosis have predominantly liver-related events, whereas those with bridging fibrosis have predominantly nonhepatic cancers and vascular events.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology. 2018. PMID: 29733831. doi:10.1053/j.gastro.2018.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。